HK1183435A1 - Frizzled-binding agents and uses thereof - Google Patents

Frizzled-binding agents and uses thereof

Info

Publication number
HK1183435A1
HK1183435A1 HK13110799.7A HK13110799A HK1183435A1 HK 1183435 A1 HK1183435 A1 HK 1183435A1 HK 13110799 A HK13110799 A HK 13110799A HK 1183435 A1 HK1183435 A1 HK 1183435A1
Authority
HK
Hong Kong
Prior art keywords
frizzled
binding agents
binding
agents
Prior art date
Application number
HK13110799.7A
Other languages
English (en)
Chinese (zh)
Inventor
奧斯丁．
．格尼
阿龍．肯．薩拓
富米考．塔卡達．阿克塞爾羅德
蒂莫西．查爾斯．霍伊
桑吉維．
．薩蒂亞爾
薩蒂亞吉特．蘇伊特．庫馬爾．米特拉
Original Assignee
昂考梅德藥品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 昂考梅德藥品有限公司 filed Critical 昂考梅德藥品有限公司
Publication of HK1183435A1 publication Critical patent/HK1183435A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
HK13110799.7A 2008-09-26 2013-09-23 Frizzled-binding agents and uses thereof HK1183435A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10063908P 2008-09-26 2008-09-26
US14405809P 2009-01-12 2009-01-12
US14428409P 2009-01-13 2009-01-13
US17674109P 2009-05-08 2009-05-08
PCT/US2009/058635 WO2010037041A2 (en) 2008-09-26 2009-09-28 Frizzled-binding agents and uses thereof

Publications (1)

Publication Number Publication Date
HK1183435A1 true HK1183435A1 (en) 2013-12-27

Family

ID=42060431

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13110799.7A HK1183435A1 (en) 2008-09-26 2013-09-23 Frizzled-binding agents and uses thereof

Country Status (20)

Country Link
US (6) US7982013B2 (pt)
EP (1) EP2331136B1 (pt)
JP (3) JP5792621B2 (pt)
KR (1) KR101711672B1 (pt)
CN (2) CN103002911B (pt)
AU (1) AU2009296246B2 (pt)
BR (1) BRPI0919473A2 (pt)
CA (1) CA2738485A1 (pt)
DK (1) DK2331136T3 (pt)
ES (1) ES2663536T3 (pt)
HK (1) HK1183435A1 (pt)
IL (1) IL211742A (pt)
MX (1) MX2011003183A (pt)
NZ (1) NZ592338A (pt)
PT (1) PT2331136T (pt)
RU (1) RU2579897C2 (pt)
SG (1) SG190568A1 (pt)
TW (1) TWI506037B (pt)
WO (1) WO2010037041A2 (pt)
ZA (1) ZA201101896B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5368798B2 (ja) * 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断し処置するための組成物および方法
WO2010030631A1 (en) * 2008-09-09 2010-03-18 Molex Incorporated Connector guide
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN103025352B (zh) * 2010-05-05 2017-07-11 纽约大学 金黄色葡萄球菌杀白细胞素及其治疗组合物和用途
US20130210733A1 (en) * 2010-06-17 2013-08-15 Cytokinetics, Inc. Methods of treating lung disease
EP2585098B1 (en) 2010-06-28 2014-08-27 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
PT2686347T (pt) 2011-03-16 2018-07-05 Argenx Bvba Anticorpos dirigidos contra cd70
WO2012135637A2 (en) * 2011-04-01 2012-10-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibition of macrophage-synthesized wnt7b to inhibit tumor angiogenesis and metastasis
EP2514765A1 (en) * 2011-04-18 2012-10-24 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Gpr177 as target and marker in tumors
AU2012271413B2 (en) * 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
JP6121902B2 (ja) * 2011-06-21 2017-04-26 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ２の細胞外領域蛋白質のトランケート体を含む蛋白質、および該蛋白質を含有する骨疾患治療用医薬組成物
KR20140048276A (ko) 2011-07-15 2014-04-23 온코메드 파마슈티칼스, 인크. Rspo 결합제 및 이의 용도
EP3783028A1 (en) * 2011-08-12 2021-02-24 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
EP2911691B1 (en) * 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
EP2767549A1 (en) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP6617239B2 (ja) * 2013-08-14 2019-12-11 サイドゥ サチデーブ Ｆｒｉｚｚｌｅｄタンパク質に対する抗体及びその使用方法
CA2931975A1 (en) * 2013-12-02 2015-06-11 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2015101998A1 (en) 2014-01-02 2015-07-09 The Chaim Sheba Medical Center Frizzled receptor antibodies for treatment of cancer
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
CA2952315A1 (en) * 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
EP3180027A4 (en) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CN106714822A (zh) * 2014-08-27 2017-05-24 昂科梅德制药有限公司 用于治疗癌症的组合治疗
EP3191526B1 (en) 2014-09-12 2023-02-22 The Board of Trustees of the Leland Stanford Junior University Wnt signaling agonist molecules
WO2016197071A1 (en) 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
BR112018007525A2 (pt) 2015-10-16 2018-10-30 Kansas State University Research Foundation composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas
CA3009999A1 (en) * 2016-01-28 2017-08-03 Jill Helms Wnt compositions and methods for serum-free synthesis
CA3014498A1 (en) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
EP3509616A1 (en) * 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
TWI762516B (zh) * 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
CN108220429A (zh) * 2016-12-14 2018-06-29 北京基石生命科技有限公司 检测人fzd7基因表达量和相对表达量的引物对
EP3574019A4 (en) 2017-01-26 2021-03-03 Surrozen, Inc. TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF
EP3728323A4 (en) * 2017-12-19 2022-01-26 Surrozen Operating, Inc. ANTI-FZD ANTIBODIES AND METHODS OF USE
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SUBSTITUTION MOLECULES AND THEIR USES
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US11643691B2 (en) 2018-04-13 2023-05-09 Duke University Predictive biomarkers for cancer immunotherapy and methods of using same
CN109358188B (zh) * 2018-09-05 2021-06-11 暨南大学 一种药物筛选方法、试剂盒及其应用
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療
WO2021026652A1 (en) * 2019-08-12 2021-02-18 Modmab Therapeutics Inc. Frizzled receptor antibodies and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
AU2022345976A1 (en) * 2021-09-14 2024-02-29 Surrozen Operating, Inc. Modulation of wnt signalling in pulmonary disorders
WO2023250402A2 (en) 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4411990A (en) 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4612282A (en) 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US5019497A (en) 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5087570A (en) 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5994617A (en) 1988-09-19 1999-11-30 Hsc Research Development Corporation Engraftment of immune-deficient mice with human cells
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US6583115B1 (en) 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en) 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5753229A (en) 1991-09-25 1998-05-19 Mordoh; Jose Monoclonal antibodies reactive with tumor proliferating cells
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
US5869282A (en) 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5654183A (en) 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
CA2140884A1 (en) 1992-07-27 1994-02-03 David J. Anderson Mammalian multipotent neural stem cells
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5928947A (en) 1992-07-27 1999-07-27 California Institute Of Technology Mammalian multipotent neural stem cells
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
DE69333969T2 (de) 1992-10-30 2006-09-14 The General Hospital Corp., Boston Wechselwirkendes Fallensystem zur Isolierung von Proteinen
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JP3106021B2 (ja) 1992-11-30 2000-11-06 キヤノン株式会社 パターンデータの圧縮方法及び装置と出力方法及び装置
WO1994018987A1 (en) 1993-02-19 1994-09-01 Nippon Shinyaku Co., Ltd. Drug composition containing nucleic acid copolymer
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
DE69534166T2 (de) 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
EP1505159B1 (en) 1995-03-17 2008-05-28 John Wayne Cancer Institute Detection of breast metastases with a multiple marker assay
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5633161A (en) 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6117985A (en) 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
ATE442373T1 (de) 1995-06-28 2009-09-15 Imp Cancer Res Tech Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
PT1568772E (pt) 1995-09-21 2010-04-14 Genentech Inc Variantes da hormona do crescimento humana
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
WO1997019172A1 (fr) 1995-11-17 1997-05-29 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide suppresseur et de differenciation
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
ES2177964T3 (es) 1996-03-30 2002-12-16 Science Park Raf S P A Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
WO1997045143A1 (en) 1996-05-31 1997-12-04 The National American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
AU723836B2 (en) 1996-08-29 2000-09-07 Regents Of The University Of California, The Kuz, a novel family of metalloproteases
JP4299886B2 (ja) 1996-09-24 2009-07-22 タノックス インコーポレイテッド アポトーシス関連ペプチドをコードする遺伝子ファミリー、それによってコードされるペプチド、およびそれらの使用方法
ATE229810T1 (de) 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
DK1864999T3 (da) 1996-11-27 2009-06-29 Genentech Inc Affinitetsoprensning af polypeptid på protein A-matrix
US5859535A (en) 1997-02-12 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy System for determining size and location of defects in material by use of microwave radiation
ATE363652T1 (de) 1997-03-07 2007-06-15 Clare Chemical Res Inc Fluorometrischer nachweis mit sichtbarem light
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US5861832A (en) 1997-03-27 1999-01-19 Lucent Technologies Inc. Analog-to-digital converter having amplifier and comparator stages
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6121045A (en) 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
EP0972041B2 (en) 1997-04-04 2017-01-18 Millennium Pharmaceuticals, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
ES2284205T3 (es) 1997-05-14 2007-11-01 Asahi Kasei Kabushiki Kaisha Nuevo inhibidor de diferenciacion.
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them
AU8162898A (en) 1997-06-18 1999-01-04 Trustees Of Columbia University In The City Of New York, The Angiogenic modulation by notch signal transduction
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6136952A (en) 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
AU756549B2 (en) 1997-07-11 2003-01-16 Crucell Holland B.V. Interleukin-3 gene therapy for cancer
EP1004699A4 (en) 1997-08-07 2000-11-08 Sumitomo Corp METHOD FOR PRODUCING WEB AND KNITTED GOODS USING SERICIN FOR FIXING YARN AND THE WEAVED AND KNITTED GOODS PRODUCED BY THIS PROCESS
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6197523B1 (en) 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US20020151543A1 (en) 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
CA2337492A1 (en) 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
JP2003528029A (ja) 1998-08-14 2003-09-24 アヴェンティス ファーマシューティカルズ インコーポレイテッド 遺伝子治療用のアデノウイルス配合物
KR20020013464A (ko) 1998-08-27 2002-02-20 추후제출 이종 유전자의 전달을 위한 표적화된 아데노바이러스 벡터
GB9819681D0 (en) 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU765485B2 (en) 1998-11-02 2003-09-18 Curis, Inc. Functional antagonists of hedgehog activity
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20030119029A1 (en) 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
CA2375700A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. Polymer conjugates of hedgehog proteins and uses
AU6069300A (en) 1999-07-02 2001-01-22 Chiron Corporation Novel human genes and gene expression products
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001026643A1 (en) 1999-10-14 2001-04-19 The Wistar Institute Inhibition of tumorigenic properties of melanoma cells
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
US20040048249A1 (en) 2000-01-21 2004-03-11 Tang Y. Tom Novel nucleic acids and secreted polypeptides
US6756511B2 (en) 2000-01-24 2004-06-29 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
EP1252192B1 (en) 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
AU2001268513A1 (en) 2000-06-17 2002-01-02 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
WO2001098354A2 (en) 2000-06-21 2001-12-27 Incyte Genomics, Inc. Human receptors
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
DE10031380A1 (de) 2000-06-28 2002-01-10 Merck Patent Gmbh Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
AU2001278070A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Basal cell markers in breast cancer and uses thereof
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20020151487A1 (en) 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US7083832B2 (en) 2000-09-01 2006-08-01 Displaytech, Inc. Partially fluorinated liquid crystal material
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
NZ526312A (en) 2000-12-13 2004-11-26 Borean Pharma As Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
US7413873B2 (en) 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US20020169300A1 (en) 2001-01-30 2002-11-14 Waterman Marian L. Method of detection and treatment of colon cancer by analysis of beta-catenin-sensitive isoforms of lymphoid enhancer factor-1
US20030064384A1 (en) 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
IL142481A0 (en) 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
DE60237969D1 (de) 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
WO2002102978A2 (en) 2001-06-15 2002-12-27 Genentech, Inc. Human growth hormone antagonists
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040023244A1 (en) 2001-06-21 2004-02-05 Griffin Jennifer A Receptors
DE60221987T2 (de) 2001-06-22 2008-05-15 Stemcells, Inc., Palo Alto Le-zellen (liver engrafting cells), assays und verwendungen davon
WO2003000893A2 (en) 2001-06-26 2003-01-03 Decode Genetics Ehf. Nucleic acids encoding g protein-coupled receptors
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
EP2216022B1 (en) 2001-07-02 2015-01-07 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
WO2003004045A2 (en) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2002365066A1 (en) 2001-07-18 2003-07-09 American Red Cross Mutant proteinase inhibitors and uses thereof
PL372212A1 (en) 2001-08-03 2005-07-11 Schering Corporation Novel gamma secretase inhibitors
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
US7053547B2 (en) 2001-11-29 2006-05-30 Universal Display Corporation Increased emission efficiency in organic light-emitting devices on high-index substrates
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
JP2005511754A (ja) 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
RU2004122702A (ru) 2001-12-26 2005-04-20 Иммуномедикс, Инк. (Us) Способы получения полиспецифичных, поливалентных средств из vh и vl доменов
US6713206B2 (en) 2002-01-14 2004-03-30 Board Of Trustees Of University Of Illinois Electrochemical cells comprising laminar flow induced dynamic conducting interfaces, electronic devices comprising such cells, and methods employing same
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
US20030185829A1 (en) 2002-03-12 2003-10-02 Erich Koller Jagged 2 inhibitors for inducing apoptosis
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
CA2484930A1 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US20040014111A1 (en) 2002-05-24 2004-01-22 Jun Li Methods for the identification of IKKalpha function and other genes useful for treatment of imflammatory diseases
EP2365004B1 (en) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membrane associated tumor endothelium markers
WO2005004912A1 (en) 2003-07-11 2005-01-20 Oncotherapy Science, Inc. Method for treating synovial sarcoma
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
AU2003256079A1 (en) 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
US20040058217A1 (en) 2002-09-20 2004-03-25 Ohlsen Leroy J. Fuel cell systems having internal multistream laminar flow
GB0221952D0 (en) 2002-09-20 2002-10-30 Novartis Forschungsstiftung Wnt mediated ErbB1 signalling,compositions and uses related thereto
US20040247593A1 (en) 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
WO2004053069A2 (en) 2002-12-06 2004-06-24 The Board Of Trustees Of The Leland Stanford Junior University PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF β-CATENIN SIGNALING PATHWAYS
US7803783B2 (en) 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
WO2004073657A2 (en) 2003-02-19 2004-09-02 Protein Design Labs, Inc. Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
WO2005031003A1 (en) 2003-09-22 2005-04-07 The Regents Of The University Of California Mutations in wnt-frizzled signaling pathways associated with osteoarthritis
US6894522B2 (en) 2003-10-06 2005-05-17 International Business Machines Corporation Specific site backside underlaying and micromasking method for electrical characterization of semiconductor devices
CN1981054A (zh) 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
CA2580803C (en) 2004-09-21 2016-06-14 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
WO2006036175A2 (en) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
CA2580780A1 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
DE102004050620A1 (de) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
JP2008520583A (ja) 2004-11-15 2008-06-19 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー Ｗｎｔ自己分泌シグナル伝達を改変するための組成物および方法
EP1817427B1 (en) * 2004-11-24 2010-09-08 F. Hoffmann-La Roche AG Method for determining genotoxicity
US7635530B2 (en) 2005-03-21 2009-12-22 The Board Of Trustees Of The University Of Illinois Membraneless electrochemical cell and microfluidic device without pH constraint
US20090311243A1 (en) 2005-05-30 2009-12-17 Astrazeneca Ab Methods for Identifying FZD8 Modulators and the Use of such Modulators for Treating Osteoarthritis
US20070014776A1 (en) 2005-06-09 2007-01-18 Gimeno Ruth E Identification of adiponutrin-related proteins as esterases and methods of use for the same
US20070072239A1 (en) 2005-09-26 2007-03-29 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
AU2006294511B2 (en) 2005-09-28 2011-11-17 Zymogenetics, Inc IL-17A and IL-17F antagonists and methods of using the same
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP5368798B2 (ja) 2005-10-31 2013-12-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断し処置するための組成物および方法
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
US20080171319A1 (en) 2006-02-06 2008-07-17 Mickey Urdea Osteoporosis associated markers and methods of use thereof
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007253586A1 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity
WO2007148417A1 (en) 2006-06-21 2007-12-27 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
US20080118432A1 (en) 2006-09-07 2008-05-22 Ivan Bergstein Monitoring cancer stem cells
CA2662041A1 (en) 2006-09-08 2008-03-13 Genentech, Inc. Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
CA2662508A1 (en) 2006-09-19 2008-07-10 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
US20100130374A1 (en) 2006-09-29 2010-05-27 Annuska Maria Glas High-throughput diagnostic testing using arrays
JP5588175B2 (ja) * 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
CA2668714A1 (en) 2006-11-14 2008-05-22 Novartis Ag Methods of treating, diagnosing or detecting cancer
US8063066B2 (en) 2007-03-19 2011-11-22 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
CL2008001373A1 (es) 2007-05-11 2008-11-21 Bayer Schering Pharma Ag Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
EP2175885B1 (en) 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
KR20150091434A (ko) 2007-07-30 2015-08-10 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
DK3156414T3 (da) 2007-09-26 2020-03-09 Intrexon Corp Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EA201000673A1 (ru) 2007-11-05 2011-04-29 Новартис Аг СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
US8022057B2 (en) 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
EP2260102A1 (en) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
DE202008004821U1 (de) 2008-04-07 2008-06-12 Heil, Roland Siebdruckform
FR2936255B1 (fr) 2008-09-19 2010-10-15 Galderma Res & Dev Modulateurs de fzd2 dans le traitement de l'alopecie
US20130295106A1 (en) 2008-09-26 2013-11-07 Oncomed Pharmaceuticals, Inc. Frizzled-Binding Agents And Uses Thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010038756A1 (ja) 2008-09-30 2010-04-08 協和発酵キリン株式会社 Frizzled1、Frizzled2又はFrizzled7細胞外システインリッチドメインを含む蛋白質を含有する骨疾患治療用医薬組成物
US20100169025A1 (en) 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
CA2972379A1 (en) 2009-03-11 2010-09-16 Ardea Biosciences, Inc. Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
EP2585098B1 (en) 2010-06-28 2014-08-27 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP3838922A1 (en) 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング

Also Published As

Publication number Publication date
JP2012503990A (ja) 2012-02-16
JP2017200487A (ja) 2017-11-09
US20130252326A1 (en) 2013-09-26
RU2011110405A (ru) 2012-11-10
TW201023881A (en) 2010-07-01
WO2010037041A2 (en) 2010-04-01
RU2579897C2 (ru) 2016-04-10
US20150232554A1 (en) 2015-08-20
EP2331136A4 (en) 2013-01-23
US8507442B2 (en) 2013-08-13
MX2011003183A (es) 2011-04-21
ZA201101896B (en) 2012-05-30
CN103002911A (zh) 2013-03-27
US20130295105A1 (en) 2013-11-07
PT2331136T (pt) 2018-03-27
JP6212070B2 (ja) 2017-10-11
SG190568A1 (en) 2013-06-28
US20110318341A1 (en) 2011-12-29
US20160326259A1 (en) 2016-11-10
EP2331136B1 (en) 2018-01-10
AU2009296246B2 (en) 2015-07-30
CN105079805A (zh) 2015-11-25
KR20110066189A (ko) 2011-06-16
US20100104574A1 (en) 2010-04-29
US7982013B2 (en) 2011-07-19
WO2010037041A3 (en) 2011-01-13
KR101711672B1 (ko) 2017-03-03
US8975044B2 (en) 2015-03-10
ES2663536T3 (es) 2018-04-13
IL211742A (en) 2015-10-29
US9273139B2 (en) 2016-03-01
EP2331136A2 (en) 2011-06-15
JP2015177802A (ja) 2015-10-08
AU2009296246A1 (en) 2010-04-01
CN103002911B (zh) 2015-08-26
CA2738485A1 (en) 2010-04-01
TWI506037B (zh) 2015-11-01
IL211742A0 (en) 2011-06-30
NZ592338A (en) 2012-11-30
BRPI0919473A2 (pt) 2017-08-29
JP5792621B2 (ja) 2015-10-14
DK2331136T3 (en) 2018-03-05
US9573998B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
HUS2300039I1 (hu) PSMA-kötõ szerek és alkalmazásaik
HK1183435A1 (en) Frizzled-binding agents and uses thereof
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
HK1196358A1 (en) Substituted pyridin-2-ones and pyridazin-3-ones -2--3-
IL210804A (en) Benzylidenehydrazides and their uses
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
HK1203980A1 (en) Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb
GB0914644D0 (en) Novel agents and uses thereof
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
EP2247601A4 (en) THIAZOPYRIMIDINONE AND APPLICATIONS THEREOF
EP2268289A4 (en) ANTI-INFECTIVES AND USES THEREOF
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
GB0813359D0 (en) Halfin and/or platerfin
GB0707069D0 (en) Methods and uses
GB0808857D0 (en) Methdos and uses
HU0800405D0 (en) Ewnvironment-friendly biocidis and use thereof
GB0910620D0 (en) Agents and uses thereof
GB0810609D0 (en) Methods and uses
GB0816523D0 (en) Methods and uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191002